AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential
A research team analyzing data on a computer screen, uncovering details about the antibody discovery platform.
AbCellera Biologics Inc. (NASDAQ:ABCL) is an AI-powered biotechnology company specializing in antibody discovery. Founded in 2012, the company integrates cutting-edge technology, advanced data science techniques, and interdisciplinary expertise to streamline the development of innovative antibody medicines. These medicines target a range of health issues, including cancer, autoimmune disorders, and metabolic conditions, addressing critical therapeutic needs in the biopharmaceutical landscape. AbCellera's pipeline includes promising candidates such as ABCL635, designed to tackle metabolic and endocrine conditions, and ABCL575, which is focused on treating T-cell-mediated autoimmune conditions like atopic dermatitis. Both programs remain in preclinical stages, with Clinical Trial Applications expected to commence by 2025, a milestone that underscores AbCellera's commitment to advancing its pipeline with precision and speed.
AbCellera's success has been bolstered by strategic collaborations with industry giants such as Eli Lilly, Biogen, and AbbVie. These partnerships have enabled the company to leverage partner insights, cutting-edge technologies, and shared expertise to develop highly optimized clinical candidates. Since its inception, AbCellera has initiated an impressive 96 partner programs, with 16 molecules having reached clinical trials, a testament to the effectiveness of its unique platform. The company's focus extends beyond partnerships, as it has heavily invested in its research infrastructure. By the end of 2025, AbCellera aims to complete its clinical manufacturing facilities, a significant step that will position the company to efficiently bring next-generation antibody therapeutics to market while maintaining high standards of innovation and quality.
In terms of financial performance, AbCellera Biologics Inc. (NASDAQ:ABCL) demonstrated a solid topline of $4.24 million for the first quarter of 2025, bolstered by milestone payments and antibody discovery collaborations. For the full year 2024, the company reported a topline of $28.8 million, further solidifying its financial robustness. With a substantial cash position of $540 million, AbCellera is well-equipped to sustain its growth trajectory. On 15th May, 2025, analysts downgraded their estimates based on revenue estimates being lower than expectations. Overall, however, analysts remain optimistic about the stock, highlighting an average share price projection of $11.43 over the next twelve months, presenting an upside potential of 474.37%.
Overall, AbCellera Biologics Inc. (NASDAQ:ABCL) ranks 7th on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of ABCL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABCL and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy
Disclosure: None. This article is originally published at Insider Monkey.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Why Baidu Stock Wilted on Wednesday
Key Points The Chinese tech industry giant reported its second-quarter results that morning. It posted declines in both revenue and adjusted profitability. 10 stocks we like better than Baidu › Veteran Chinese tech giant Baidu (NASDAQ: BIDU) looked rather tired to equity investors on Wednesday. They didn't seem wowed by the company's latest earnings release and expressed this by collectively trading their American depositary shares (ADS) down by almost 3%. This was a steeper fall than the 0.2% endured by the bellwether S&P 500 index. Top- and bottom-line slides Baidu's second-quarter results, published well before market open that day, revealed that the company's revenue slumped by 4% year over year to 32.7 billion yuan ($4.55 billion). That was slightly below the consensus analyst estimate of 32.9 billion yuan ($4.58 billion). The decline and miss might have been more pronounced had it not been for the company's artificial intelligence (AI)-boosted offerings. Baidu quoted CEO Robin Li as saying that its AI Cloud business "continued to deliver robust and healthy revenue growth, supported by our strengthening full-stack AI capabilities and comprehensive end-to-end AI products and solutions." It didn't help push the bottom line higher, however, as non-GAAP (adjusted) net income fell by 35% to just under 4.8 billion yuan ($668 million). On a per-ADS basis, the company's profitability was 13.58 yuan ($1.89). On the bright side, this was a bit higher than the average analyst estimate of 13.33 yuan ($1.86) per ADS. Motoring into a better future? In its earnings release, Baidu pointed to AI as a potential engine of growth. On the subject of engines, it also clearly has high hopes for the robotaxis coming from its mobility unit, Apollo Go. It said that it is a leading company in robotaxi markets with both left- and right-hand drive regimes. Should you buy stock in Baidu right now? Before you buy stock in Baidu, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Baidu wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,781!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,076,588!* Now, it's worth noting Stock Advisor's total average return is 1,055% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Baidu. The Motley Fool has a disclosure policy. Why Baidu Stock Wilted on Wednesday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Nvidia Stock Falls Despite Bullish Calls From KeyBanc and Susquehanna
This article first appeared on GuruFocus. Aug 20 Nvidia Corporation (NASDAQ:NVDA) shares fell about 2.5% on Wednesday morning even as two Wall Street firms raised their price targets ahead of the company's quarterly earnings report next week. Warning! GuruFocus has detected 5 Warning Signs with NVDA. KeyBanc Capital Markets lifted its target on the chipmaker to $215 from $190, while keeping an Overweight rating. Analyst John Vinh said he expects Nvidia to post strong fiscal second-quarter results for July but guide slightly below consensus for the October quarter. He noted that the company's outlook likely excludes revenue from China due to pending license approvals and uncertain timing. According to Vinh, including China could add an incremental $2 billion to $3 billion in sales, driven by the H20 and RTX6000D processors. Susquehanna also raised its price target, moving to $210 from $180, and kept a Positive rating. Analyst Christopher Rolland sees continued momentum across Nvidia's data center business. Consensus estimates call for Nvidia to earn $1.01 per share on revenue of $45.92 billion in the coming quarter. The company is scheduled to release results on Aug. 27. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
NBC News
37 minutes ago
- NBC News
Nasdaq, S&P 500 end lower as investors sell tech, buy less pricey sectors
The Nasdaq and S&P 500 fell on Wednesday as investors sold tech stocks and moved into less highly valued sectors, as they also awaited remarks from Federal Reserve officials at their Jackson Hole symposium this week. Tech stocks, which drove much of the recovery from Wall Street's April selloff, have been pulling back. The S&P 500 technology index .SPLRCTwas down on the day, while sectors such as energy, healthcare and consumer staples rose. 'A broader lens tells you it's more of a rotation than a true sell off,' said Allspring's senior portfolio manager, Bryant van Cronkhite. 'Tech valuations look extended in the context of inflated spending today. Number two, I would say that there are a lot of pockets of the market that look very attractive from a valuation standpoint and they've been broadly ignored.' According to preliminary data, the S&P 500 lost 16.40 points, or 0.26%, to end at 6,394.97 points, while the Nasdaq Composite lost 144.76 points, or 0.68%, to 21,170.19. The Dow Jones Industrial Average rose 1.48 points, or 0.00%, to 44,923.75. Analysts listing other factors behind the tech sell-off mentioned OpenAI CEO Sam Altman's comments last week about artificial intelligence stocks being 'in a bubble,' and a Massachusetts Institute of Technology study that showed many tech companies were struggling to translate AI into actual profits. Some investors also worried about government interference in the private sector. President Donald Trump's administration is looking into taking equity stakes in chip firms such as IntelINTC.O, weeks after unprecedented revenue-sharing deals with Nvidia and AMD. Nvidia, Advanced Micro Devices, Intel and Micron fell. Nvidia's quarterly results on August 27 are keenly awaited for clues on demand for artificial intelligence. Other megacap growth names such as Apple and Meta also came under pressure. Minutes from the Fed's July meeting, where interest rates were left unchanged, showed almost all policymakers viewed it as appropriate to maintain the target range for the federal funds rate at 4.25% to 4.50%, despite two dissenters. Fed Chair Jerome Powell is expected to speak on Friday at the central bank's annual conference in Jackson Hole, Wyoming. His remarks will be closely watched for policy signals. Investors have been pricing in a 25-basis-point rate cut in September, according to data compiled by LSEG. Meanwhile, investors also monitored Trump's call for the resignation of Fed Governor Lisa Cook, with the president citing allegations that she was involved in mortgage fraud. Earnings from big retailers, seen as a barometer for the health of the American consumer, are also due this week as sentiment has taken a hit from concerns that tariffs could drive prices higher. Target after the company named a new CEO and retained its annual forecasts that were lowered in May.
